ClinicalTrials.gg
RecruitingNCT06960798Updated Oct 13, 2026

Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)

An observational study in Prostate Cancer and Renal Cell Carcinoma (RCC), sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Oklahoma · Observational

How we know

Updated Oct 13, 2026Start date movedEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
179th of 478
300 · median 158
Started
2026
with 175 others
Observational
483 of 3,597
100 open now
Primary completion
2028-10
later than 717 of 968 live
Registered
3,353rd of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 179th largest by planned enrollment of the 478 observational ones that give a count, is one of 176 that started in 2026, is one of 483 observational ones, reaches primary completion later than 717 of the 968 other live ones, and was the 3,353rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

599 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prespecified cancers of interest. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of your cancer.

Read the detailed description

This study aims to establish a comprehensive database of Native American (NA) patients diagnosed with prostate cancer (PC) and Renal cell carcinoma (RCC) , focusing on an in-depth characterization of the genomic landscape. Archived tumor tissue collected at screening and peripheral blood samples obtained within the first year of enrollment will serve as the basis for comprehensive molecular analyses. Whole exome sequencing (WES) and whole transcriptome sequencing (RNA-seq) will be performed to characterize and delineate the genomic and transcriptomic landscape of the study cohorts. Oversight will be maintained by the Institutional Review Board and an independent Native American Advisory Board to ensure cultural appropriateness, transparency, and sustained community engagement throughout the research process. The overarching objective is to generate insights that will inform the development of personalized treatment strategies in the future.

03

Conditions studied

  • Prostate Cancer
  • Renal Cell Carcinoma (RCC)

Keywords

  • Genomic Profile
  • Native American
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This clinical trial will focus on addressing the underrepresented Native American population served by the Urology Oncology Department at Stephenson Cancer Center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
  • At least 18 years-of-age at the time of signature of the informed consent form (ICF).
  • Patients who self-identify as Native American.
  • Patients with a proven diagnosis of PC and RCC (any stage).
  • Availability of most recent archived tumor samples.

Exclusion criteria

Exclusion Criteria:

  • Patients not of Native American descent or identity.
  • Patient does not have available.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort (A) Native American Men with Prostate Cancer

    150 patients will be assigned in this cohort

    Other: Bio-specimen Collection · Other: Blood Draw

  • Cohort (B) Native American Patients with Renal Cell Carcinoma

    150 patients will be assigned in this cohort

    Other: Bio-specimen Collection · Other: Blood Draw

Interventions

  • OtherBio-specimen Collection

    Tissue samples will be taken from existing archived collections and sent for further analysis.

  • OtherBlood Draw

    Blood samples will be collected within the first year of enrollment.

06

What researchers measure

Primary outcomes

  1. Disease-specific genomic and transcriptomic profiles in Native American patients

    The frequency and distribution of somatic genomic alterations, including single-nucleotide variants, insertions/deletions, copy-number alterations, tumor mutational burden, and clinically actionable alterations, together with gene-expression signatures and molecular pathway activity identified by whole-exome sequencing and whole-transcriptome sequencing in each disease-specific Native American cohort.

    Time frame: 1-3 years

Secondary outcomes

  1. Differential genomic and transcriptomic features between Native American and non-Hispanic White cohorts

    Differences in the frequency and distribution of somatic genomic alterations, gene-expression signatures, molecular subtypes, and pathway-level enrichment between Native American disease-specific cohorts and prespecified publicly available or approved non-Hispanic White reference cohorts.

    Time frame: 1-3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 23 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 7, 2025
StartEst.
Nov 2, 2026was Oct 2026
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2, 2026→Nov 2, 2026
Oct 13, 2026
Enrollment
150→300
Oct 13, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients with a pathologically proven diagnosis of PC and RCC (any stage).
Oct 13, 2026
Interventions
Arms added: Cohort (A) Native American Men with Prostate Cancer·Cohort (B) Native American Patients with Renal Cell Carcinoma; arms removed: Native American Group
Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Difference in the genomic profiles of Prostate CancerNow Disease-specific genomic and transcriptomic profiles in Native American patientsTime frame: 1-3 years
Oct 13, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Comparison of Genomic ProfilesNow Differential genomic and transcriptomic features between Native American and non-Hispanic White cohortsTime frame: 1-3 years
Oct 13, 2026
Contact
Study contact changed: A•••@ouhsc.edu · •••4022→A•••@ou.edu · •••4022. See the current contact
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • OU Health Stephenson Cancer Center · Oklahoma City, United StatesContact A•••@ouhsc.edu→A•••@ou.edu
Oct 13, 2026
Title
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Oct 2, 2026→Nov 2, 2026
    Enrollment 150→300
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with a pathologically proven diagnosis of PC and RCC (any stage).
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Difference in the genomic profiles of Prostate CancerNow Disease-specific genomic and transcriptomic profiles in Native American patientsTime frame: 1-3 years
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Comparison of Genomic ProfilesNow Differential genomic and transcriptomic features between Native American and non-Hispanic White cohortsTime frame: 1-3 years
    Interventions Arms added: Cohort (A) Native American Men with Prostate Cancer·Cohort (B) Native American Patients with Renal Cell Carcinoma; arms removed: Native American Group
    Contact Study contact changed: A•••@ouhsc.edu · •••4022→A•••@ou.edu · •••4022. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • OU Health Stephenson Cancer Center · Oklahoma City, United StatesContact A•••@ouhsc.edu→A•••@ou.edu
    Title Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06960798
Responsible party
Sponsor
First posted
May 7, 2025
Start date
Nov 2, 2026 (estimated)
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Lead Onco Nurse
Contact
SCC-IIT-Office@ouhsc.edu
405-271-8777
Adanma Ayanambakkam, MD, MS
Contact
Adanma-Ayanambakkam@ou.edu
405-271-4022
Adanma Ayanambakkam, MD, MS
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion